COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #67
Source   PDF   Share   Tweet
See all 143 studies
6/25
Inconc.
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Gendebien et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218244 (Letter)
Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxych loroquine use and immunosuppressive treatments
Small study of 152 SLE patients taking HC Q with a phone survey for COVID-19 suggestive symptoms. There was 2 hospitalizations (group not identified) and no ICU or death cases. A similar percentage of suspected infections were reported for HC Q users and non-HC Q users, RR 0.96, p = 0.93.
There was no mortality and severity was not analyzed to determine if HC Q treated patients fared better. No adjustment for concomitant medications or severity of SLE. Only 5 cases were PCR confirmed.
COVID-19 case, ↓3.9%, p=0.93
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit